J. Molner (MOLNR) H2 2024 earnings summary

Executive summary

• Revenue grew 272% year-over-year to EUR 2,294,628, driven by new product launches and expanded R&D services, especially in the U.S. and Europe.

• Key launches included Lidocaine HCL Topical Solution USP, 4% and full-year sales of Hydrocortisone Butyrate Lotion, 0.1%.

• Strategic partnerships secured, including a U.S. development agreement and expanded access via CMS.

• Workforce expanded to 33 employees, focusing on R&D capacity.

Financial highlights

• Revenue: EUR 2,294,628 in 2024 (2023: EUR 617,563), up 272% year-over-year.

• Net loss: EUR -2,438,621 in 2024 (2023: EUR -1,085,185), reflecting higher costs and investments.

• Direct costs: EUR 1,935,768 (84% of revenue); excluding pass-through, direct cost ratio was 70%.

• Operating expenses: EUR 1,128,559, up 39% year-over-year, mainly due to regulatory and legal costs.

• Interest expenses rose 116% to EUR 339,729, linked to increased loan obligations.

Outlook and guidance

• Focus remains on expanding generic drug portfolio and R&D services for U.S. and European markets.

• Strategic partnerships and regulatory approvals expected to support future growth.